Kevin J. Freise

机构：AbbVie (United States) · ORCID：0000-0001-7142-2444

发表论文 92 篇 · 总被引 2452 次 · h-index 24

代表论文

• A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (2022 · Journal of Clinical Oncology · 被引 128)
• First-in-human study of ABBV-400, a novel c-Met–targeting antibody-drug conjugate, in advanced solid tumors: Results in colorectal cancer. (2024 · Journal of Clinical Oncology · 被引 21)
• Abstract 6311: ABBV-400: An ADC delivering a novel topoisomerase 1 inhibitor to c-Met-positive solid tumors (2023 · Cancer Research · 被引 13)
• 1257MO ABBV-400, a c-Met protein-targeting antibody-drug conjugate (ADC), in patients (Pts) with advanced EGFR wildtype (WT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): Results from a phase I study (2024 · Annals of Oncology · 被引 12)
• Dose escalation results from a first-in-human study of ABBV-400, a novel c-Met–targeting antibody-drug conjugate, in advanced solid tumors. (2023 · Journal of Clinical Oncology · 被引 12)
• 1439P ABBV-400, a c-Met protein–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced gastric/gastroesophageal junction adenocarcinoma (GEA): Results from a phase I study (2024 · Annals of Oncology · 被引 9)